Johnson & Johnson $JNJ Shares Sold by Bank of Montreal Can

Bank of Montreal Can trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,082,999 shares of the company’s stock after selling 109,364 shares during the quarter. Bank of Montreal Can owned about 0.17% of Johnson & Johnson worth $757,070,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Legal & General Group Plc lifted its holdings in shares of Johnson & Johnson by 2.8% in the third quarter. Legal & General Group Plc now owns 19,450,064 shares of the company’s stock valued at $3,606,431,000 after buying an additional 532,790 shares during the period. Banque Cantonale Vaudoise boosted its stake in Johnson & Johnson by 1.8% during the third quarter. Banque Cantonale Vaudoise now owns 71,290 shares of the company’s stock valued at $13,218,000 after buying an additional 1,275 shares in the last quarter. Vestcor Inc grew its holdings in Johnson & Johnson by 17.6% during the third quarter. Vestcor Inc now owns 180,698 shares of the company’s stock worth $33,505,000 after acquiring an additional 26,990 shares during the period. Clarkston Capital Partners LLC raised its position in Johnson & Johnson by 2.3% in the third quarter. Clarkston Capital Partners LLC now owns 124,610 shares of the company’s stock worth $23,105,000 after acquiring an additional 2,753 shares in the last quarter. Finally, Sienna Gestion lifted its holdings in Johnson & Johnson by 9.3% in the 3rd quarter. Sienna Gestion now owns 142,127 shares of the company’s stock valued at $24,027,000 after acquiring an additional 12,073 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on JNJ shares. Leerink Partners raised their price objective on shares of Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a research report on Thursday, January 22nd. Guggenheim boosted their target price on shares of Johnson & Johnson from $227.00 to $240.00 and gave the stock a “buy” rating in a report on Friday, January 23rd. Bank of America restated a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 2nd. Barclays lifted their price target on shares of Johnson & Johnson from $197.00 to $217.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 30th. Finally, Wolfe Research upped their price target on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $234.87.

Johnson & Johnson Price Performance

NYSE JNJ opened at $242.49 on Tuesday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $251.71. The company has a market cap of $584.39 billion, a PE ratio of 21.95, a PEG ratio of 2.37 and a beta of 0.34. The stock’s 50-day moving average price is $229.06 and its two-hundred day moving average price is $204.82.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The company had revenue of $24.28 billion during the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the transaction, the executive vice president directly owned 26,769 shares in the company, valued at approximately $6,540,469.77. The trade was a 45.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 30,142 shares of company stock valued at $7,360,528 in the last ninety days. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.